Hossein Borghaei, DO, MS, Offers His Advice on Staying Up to Date With Lung Cancer Research

Video

CancerNetwork® sat down with Hossein Borghaei, DO, MS, to talk about keeping track of conference and journal updates to help build and maintain knowledge around lung cancer.

CancerNetwork® spoke with Hossein Borghaei, DO, MS, of the Fox Chase Cancer Center and Thoracic Malignancies Chair for the journal ONCOLOGY®, about how clinicians can keep up with current trends in lung cancer by participating in various conferences, reading pertinent journal articles, and keeping up to date with social media.

Transcript:

Don’t miss updates. Lung cancer treatment is moving very quickly. There are a lot of nuances now and it’s not as simple as giving the same chemotherapy to everybody. These updates can be very important from various meetings, such as [the American Society of Clinical Oncology Annual Meeting, the World Conference on Lung Cancer, the European Society for Medical Oncology Congress, and American Association for Cancer Research Annual Meeting] because it could have an impact on clinical practice and patient care. Staying up to date is even more important in the world of lung cancer. In the last 10 to 12 years, we’ve seen a lot of changes in lung cancer and I’m hoping that the evolution will continue. We’re going to see refinement with more drugs and more methods made available for assessments. I think it’s important to stay up to date, which is why programs like CME and some of the other things that are done is quite important, especially reading the actual journal articles and summaries that are provided. I think those are all good.

Recent Videos
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Related Content